PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel-based pharmaceutical company Roche has obtained a CE mark for its diagnostic procedure, which identifies patients with non-small cell lung cancer (NSCLC), who are then eligible for treatment with the Novartis drug ZYKADIA.
The companion diagnostic VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody identifies the biomarker anaplastic lymphoma kinase (ALK), Roche explains in a press release. The inhibition of this biomarker can help shrink tumours in patients with non-small cell lung cancer (NSCLC) in a targeted way. NSCLC patients with this biomarker qualify for treatment with the Novartis drug ZYKADIA. This procedure is the first immunohistochemistry (IHC) test to be CE marked as a companion diagnostic for ZYKADIA.
In the press release, Ann Costello, Head of Roche Tissue Diagnostics, notes that the precise and personalised diagnostic is critical for the fight against non-small cell lung cancer, commenting that: “Expanded use of the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody to identify non-small cell lung cancer patients with an ALK-positive mutation allows us to aid clinicians and their patients in identifying appropriate treatment options.”